WANBURY

Wanbury Share Price

₹243.25 +4.35 (1.82%)

22 Jan, 2025 16:16

SIP TrendupStart SIP in WANBURY

Start SIP

Performance

  • Low
  • ₹232
  • High
  • ₹249
  • 52 Week Low
  • ₹123
  • 52 Week High
  • ₹324
  • Open Price₹233
  • Previous Close₹239
  • Volume55,103

Investment Returns

  • Over 1 Month -14.5%
  • Over 3 Month -0.02%
  • Over 6 Month + 30.16%
  • Over 1 Year + 63.26%
SIP Lightning

Smart Investing Starts Here Start SIP with Wanbury for Steady Growth!

Invest Now

Wanbury Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 797
  • P/B Ratio
  • 20.6
  • Average True Range
  • 13.78
  • EPS
  • 8.43
  • Dividend Yield
  • 0
  • MACD Signal
  • -6.4
  • RSI
  • 39.54
  • MFI
  • 46.43

Wanbury Financials

Wanbury Technicals

EMA & SMA

Current Price
₹243.25
+ 4.35 (1.82%)
pointer
  • stock-down_img
  • Bearish Moving Average 10
  • stock-up_img
  • Bullish Moving Average 6
  • 20 Day
  • ₹257.03
  • 50 Day
  • ₹260.34
  • 100 Day
  • ₹247.99
  • 200 Day
  • ₹218.34

Resistance and Support

240.33 Pivot Speed
  • R3 251.47
  • R2 248.23
  • R1 243.57
  • S1 235.67
  • S2 232.43
  • S3 227.77

What's your outlook on Wanbury?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wanbury manufactures and markets pharmaceutical products, focusing on active pharmaceutical ingredients (APIs) and formulations. The company serves global markets with a range of therapeutic solutions in areas like anti-diabetics, pain management, and gastrointestinal treatments.

Wanbury has an operating revenue of Rs. 577.20 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 10% is healthy, ROE of 200% is exceptional. The company has a high debt to equity of 293%, which can be a reason to worry. The stock from a technical standpoint is trading below to its 50DMA and around 12% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -17% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 20 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wanbury Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-12 Quarterly Results
2024-05-16 Audited Results
2024-01-24 Quarterly Results
2023-10-20 Quarterly Results & Preferential issue Inter-alia, to consider and evaluate proposals for raising of funds by way of a preferential issue/allotment and private placement to promoters/promoter group of the Company.

Wanbury F&O

Wanbury Shareholding Pattern

39.77%
0%
1.02%
0%
40.66%
18.55%

About Wanbury

  • NSE Symbol
  • WANBURY
  • BSE Symbol
  • 524212
  • ISIN
  • INE107F01022

Similar Stocks to Wanbury

Wanbury FAQs

Wanbury share price is ₹243 As on 22 January, 2025 | 16:02

The Market Cap of Wanbury is ₹796.9 Cr As on 22 January, 2025 | 16:02

The P/E ratio of Wanbury is 15 As on 22 January, 2025 | 16:02

The PB ratio of Wanbury is 20.6 As on 22 January, 2025 | 16:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23